Hospital Acquired Pneumonia
13
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
1 terminated out of 13 trials
90.0%
+3.5% vs benchmark
23%
3 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
Steriwave ICU Pilot Study
Real-World Study of Ceftazidime Avibactam in China
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
Pneumonia Pathogens' Virulence Factors, Patient Inflammatory Markers, and Their Associations With Outcomes
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections
Hospital-acquired Pneumonia in Intensive Care Unit
Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor
Validity of Biological Material Sampling in Patients With Hospital-acquired Pneumonia
Does Cricoid Pressure Reduce the Risk of Aspiration?
Early Mobility Bundle to Prevent Hospital Acquired Pneumonia (HAP) in Medical Inpatients
The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia
Colistin and Rifampicin for MDR-Acinetobacter